Researchers at EPFL reported a preclinical CAR‑T system, DROP‑CAR, that can be rapidly and reversibly switched off using the clinically approved cancer drug venetoclax. The team published their work in Nature Chemical Biology and demonstrated controllability and antitumor efficacy in mouse models. DROP‑CAR does not rely on destructive elimination of the engineered cells; instead, venetoclax induces reversible disengagement of CAR‑T cells from targets, offering clinicians a pharmacologic 'remote control' to modulate activity. The approach aims to reduce on‑target/off‑tumor toxicities and manage chronic antigen exposure and cellular exhaustion that limit CAR‑T use in solid tumors. If translated to humans, the strategy could expand CAR‑T applicability and add a clinically realistic safety valve using a drug already in routine oncology practice.